Akari TherapeuticsAKTX -7.39%32 PEG Ratio is 0.04 as of Jul. 09, 2026. GuruFocus rates AKTX with a GF Score™ of 32/100. Among 94 Biotechnology companies, Akari Therapeutics ranks better than 96.81% on this metric.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Akari Therapeutics's PEG Ratio or its related term are showing as below:
AKTX'
s PEG Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.05
Current: 0.04
During the past 13 years, Akari Therapeutics's highest PEG Ratio was 0.05. The lowest was 0.00. And the median was 0.00.
AKTX's PEG Ratio is ranked better than 96.81% of 94
companies
in the Biotechnology industry
Industry Median: 1.98
vs AKTX: 0.04
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Akari Therapeutics (NAS:AKTX) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Akari Therapeutics PEG Ratio Related Terms
Akari Therapeutics PEG Ratio Historical Data
* Premium members only.
The historical data trend for Akari Therapeutics's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Akari Therapeutics's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akari Therapeutics PEG Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akari Therapeutics's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Akari Therapeutics's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Akari Therapeutics (AKTX) has a PEG Ratio of 0.04 as of Jul. 09, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Akari Therapeutics and its competitors. According to the industry distribution chart, Akari Therapeutics ranks #3 out of 94 companies in the Biotechnology industry, placing it in the top 3.2%.
Is Akari Therapeutics' PEG Ratio too high?
Akari Therapeutics' current PEG Ratio is 0.04. The Biotechnology industry median PEG Ratio is 1.98. Akari Therapeutics' value of 0.04 is 98% below this industry median. Based on the distribution chart, Akari Therapeutics ranks #3 out of 94 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Akari Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Akari Therapeutics' PEG Ratio compare to MBRX and JAGX?
According to the Biotechnology industry distribution chart, Akari Therapeutics ranks #3 out of 94 companies for PEG Ratio. This places Akari Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median PEG Ratio is 1.98. Akari Therapeutics' value of 0.04 is 98% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Biotechnology company?
The median PEG Ratio among Biotechnology companies is 1.98, based on 94 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Akari Therapeutics's current PEG Ratio of 0.04 is 98% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Akari Therapeutics and its competitors. For the Biotechnology industry, the median PEG Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Akari Therapeutics's current PEG Ratio is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Akari Therapeutics stock overvalued right now?
Akari Therapeutics (AKTX) has a current PEG Ratio of 0.04. The current PEG Ratio is 0.04 and 98% below the Biotechnology industry median of 1.98. Akari Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Akari Therapeutics (AKTX), the current PEG Ratio is 0.04 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
32GF Score
Get the complete analysis for AKTX
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AKTX has been successfully added to your 
